Navigation Links
Breakthrough for more efficient drug development
Date:1/18/2011

Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.

The study, published today in the prestigious journal Angewandte Chemie, presents the concept of a tiny polypeptide consisting of 42 amino acids to which virtually any target-seeking organic molecule can be bound. In the body it then seeks out the designated sites to be treated. What's unique about the polypeptide is that it dramatically enhances the properties of the little molecule in a simple and very general way.

- This produces superbinders. They bind more strongly and more specifically than other alternatives, says Lars Baltzer, professor of organic chemistry, who believes it will be possible to rapidly develop new drugs much more readily with this new concept.

The whole concept goes against the grain of what is usually done in drug development. Traditionally it's usually a matter of synthesizing drugs from A to Z, with certain requirements needing to be met in order to succeed. Drugs should be low molecular (500 Da), be highly fat soluble, and have no more than ten binding sites in order to pass through the cell membrane. But the majority are ineffective or toxic, and nowadays there are also ways to get larger molecules through cell membranes. Recently therapeutic antibodies have emerged as an alternative. They're large (150,000 Da) and bind to the outside of cells, which they then "block."

The new peptide is 5,000 Da or only 1/30 as large as a typical antibody, which is smaller than was thought possible. But according to Lars Baltzer nature has always signaled that this should work.

- The human growth factor hGH uses 35 amino acids to bind to its receptor, but it turns out that only six of them are critical. The rest can be replaced without significantly changing the function. There's really nothing very special about placing a general peptide on a small molecule, but nobody has done it before, he says.

In this study the peptide was successfully bound to the inflammation marker CRP, which is an indicator of a risk of premature death in heart patients, among other things. Several other studies are underway and are proving to be equally successful.

These findings are of great importance to industry, and several large companies have shown their interest. The spin-out company that was previously formed out of Baltzer's research team is now going to further develop the concept to be able to help the drug industry determine at a considerably earlier stage than today whether a drug candidate is worth pursuing or not.


'/>"/>

Contact: Lars Baltzer
lars.baltzer@biorg.uu.se
46-070-648-2595
Uppsala University
Source:Eurekalert

Related medicine news :

1. Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeants Pet Care Products, Inc.
2. First Breakthrough in Water Heating Technology!
3. New DNA technique leads to a breakthrough in child cancer research
4. Northern Illinois Proton Center on the Verge of Major Medical Breakthrough
5. OvaCue Fertility Monitor Breakthrough Allows Women to See Fertility Color-coded on a Calendar Over Time
6. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
7. Breakthroughs in treatment of spine and back conditions
8. buySAFE, Inc. Releases a Breakthrough White Paper that is a Must Read for Every Internet Retailer Interested in Increasing Website Conversion
9. Tampa Bay Vein Treatment and Cosmetic Dermatology Practice Using New Laser Technology Some Say is the Latest Breakthrough
10. Breakthrough for babies born with severe cleft palates after experiments at ISIS
11. Gene-Targeted Cancer Fix Could Be a Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance and ... to clients in southern Montana, is announcing a focused charity effort to gather ... outreach programs offered by Zoo Montana provide students with current knowledge on the ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... MA (PRWEB) , ... June 27, 2017 , ... The ... Senate bill to repeal and replace the 2010 Patient Protection and Affordable Care Act ... compared with what would be expected under current law. , More than 20 million ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article on medGadget ... $6.81 billion by the year 2024 according to a new report. The article also ... made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... 7, 2017 Endo International plc (NASDAQ: ... the Hon. Joseph R. Goodwin , U.S. District ... West Virginia , entered a case management order ... System Products Liability Litigation (the "MDL") that includes a ... provide expert disclosures on specific causation within one hundred ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: